Open AccessAssociation between zidovudine-containing antiretroviral therapy exposure in utero and leukocyte telomere length at birth
Author(s) -
Youjin Wang,
Sean Brummel,
Erin BeilsteinWedel,
Casey Dagnall,
Rohan Hazra,
Deborah Kacanek,
Ellen G. Chadwick,
Carmen J. Marsit,
Stephen J. Chanock,
Sharon A. Savage,
Miriam C. Poirier,
Mitchell J. Machiela,
Eric A. Engels
Publication year - 2019
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002317
Subject(s) - zidovudine , in utero , telomere , confidence interval , pregnancy , medicine , relative risk , gestational age , emtricitabine , immunology , biology , physiology , fetus , viral load , antiretroviral therapy , human immunodeficiency virus (hiv) , viral disease , genetics , dna
Zidovudine (ZDV) is a nucleoside reverse transcriptase inhibitor that could cause telomere shortening through inhibition of telomerase. We examined the association between in utero exposure to ZDV and telomere length at birth in HIV-exposed-uninfected (HEU) newborns.